Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2003

View Archived Issues

New therapeutic target for type 2 diabetes: beta-cell apoptosis

Spotlight on PPAR agonists in development for diabetes mellitus

Spotlight on contraceptive research

New beta3-adrenoceptor agonists for urinary incontinence and other uses

Potassium channel-modulating series described by 4SC researchers

Selective progesterone receptor modulators prepared and tested at Schering AG

Wyeth presents new estrogenic agents with potential in menopause, endometriosis, etc.

Medinox patent covers novel NSAID prodrugs with improved safety profile

Bayer presents new p38 kinase inhibitors for COPD therapy

Seroquel approved in Europe for bipolar mania

Oral dosing of AVI-4557 tested in phase I study

Betaseron prefilled diluent syringe receives FDA approval

IPM grant to advance cyanovirin-N development

Bristol-Myers Squibb and Corgentech to jointly develop E2F decoy

Independent data support use of M6G for postoperative pain

Dual-acting anthrax vaccine designed by Boston-based team

ChemoCentryx awarded grant to develop chemokine-based immunomodulators

Wyeth advances NSP-989 into phase II

New data supports Cialis for ED

Metabolic licenses analgesic compound discovered at university

Preliminary observations from European trials of Hynic-Annexin V product

PEG-Intron Redipen approved by FDA

VaxGen enters license agreement with USAMRIID for vaccine technology

Selective erbB2 kinase inhibitor CP-654577 inhibits growth of human breast cancer

Flatfish-derived antimicrobial peptide discovered using genomic approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...